drugset / Trial / NCT00284050

Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement

NCT00284050

Phase 2 Completed 151 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This study evaluated the safety and efficacy of ranibizumab on retinal edema and visual acuity in patients with diabetic macular edema with center involvement.

Timeline

Start
2005-10
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.3 mg Intravitreal
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal